$20 million fundraising effort will support efforts to improve treatment for lung disease
UCLA Health has launched a $20 million fundraising initiative to create a new center for advanced lung disease at theDavid Geffen School of Medicine at UCLA. To date, the initiative has secured $4.37 million for the Lung Health Research Accelerator Fund, including three gifts of $1 million each from Michael and Linda Keston, William Pierpoint, and Jeffrey and Robin Raich, and a total of $1.37 million from nine other donors.The fund will support the work of Dr. John Belperio and Dr. Joseph Lynch III in the medical school ’s division of pulmonary and critical care medicine. Belperio’s research is focused on identifying the causes of and potential treatments for transplant rejection and advanced lung diseases, including chronic obstructive pulmonary disease, emphysema, idiopathic pulmonary fibrosis, sarcoidosis an d interstitial lung disease.Because of the overlap among those conditions, discoveries related to one disease could help lead to advances in understanding and treating the others.“Existing treatments for advanced lung diseases are unimpressive and leave patients with one option — lung transplantation,” said Belperio, who holds the Guitiara Pierpoint Endowed Chair in Interstitial Pulmonary Fibrosis. “Unfortunately, transplantation is not a cure, with only half of lung transplant recipients surviving five years. “Our patients deserve better. We need novel treatments that improve patients’ quality of life and ultimately...
No abstract available
The rare operation has implications for wounded soldiers, accident victims, cancer patients and those undergoing sex reassignment.
ConclusionsRecurrence influenced long-term deterioration. KL-6 was a serum biomarker for disease behavior and recurrence prediction. The results suggest the importance of CNI continuation.
Today's open access research on tryptophan and its role in age-related immune dysfunction is particularly interesting in the context of ongoing research into the changes that take place in gut microbiota with age. Other recent work has examined the way in which tryptophan production by gut microbes declines precipitously with age, as this is one of a number of compounds produced by bacteria, such as butyrate, indole, and proprionate, that are influential on long term health. It is a slow process, but researchers are uncovering the specific mechanisms linking age-related changes in gut microbe populations with declining hea...
Conclusions: There is substantial interest in learning to perform DMEK among the surgical community. Barriers identified in this survey may be addressed to help surgeons increase DMEK adoption.
Conclusions: The results indicate no difference in graft survival between PK and EK for ICE syndrome. Graft survival in ICE syndrome is intermediate between that of FED and PBK.
Conclusions: The use of alternate topical corticosteroids may be considered in cases of steroid-induced ocular hypertension after PKP because they offer good antiinflammatory prophylaxis with reduced hypertensive response.
Conclusions: DM suturing can reattach DM, especially in moderate to severe, recurrent DMD with fewer postoperative complications and thereby reduce the need for corneal transplantation.
Conclusions: Tear lipids are more ordered than meibum lipids, which could have functional consequences. The human meibum peak height ratio of the CH3/CH2 bands is not a factor related to tear film stability with age or sex. The amount of CH3 moieties relative to CH2 moieties and saturation could contribute to a higher meibum lipid order associated with a younger age, meibomian gland dysfunction, and dry eye from hematopoietic stem cell transplantation. Therefore, the hydrocarbon order may be a marker of or contribute to an unstable tear film layer.
Publication date: Available online 5 December 2019Source: Journal of Clinical and Experimental HepatologyAuthor(s): Waseem Amjad, Sandy Kotiah, Ankur Gupta, Michael Morris, Li Liu, Paul J. ThuluvathAbstractThe use of immunotherapy in transplant recipients is considered a contraindication because of very high risks for graft loss. The graft loss is to be expected since cytotoxic T-lymphocyte associated protein-4 (CTLA-4) and PD-1 pathways are implicated in graft tolerance. In this case report, we describe a woman with recurrent, disseminated hepatocellular carcinoma who was successfully treated with nivolumab, an immune checkpoint inhibitor.